Postmarket safety communications on drugs approved in Japan: A 25‐year analysis
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13803 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Yusuke Tanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan. Hauptthemen laut MEDLINE: Drug Approval, Product Surveillance, Postmarketing, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Drug safety communications (DSCs) are essential tools for communicating important postmarket serious drug safety information to healthcare professionals and patients. Previous studies characterized DSCs issued by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA); however, knowledge about the activities of the Pharmaceuticals and Medical Devices Agency (PMDA)/the Ministry of Health, Labor and Welfare (MHLW) is limited. This study characterized DSCs by the PMDA/MHLW in comparison with previously reported DSCs by the FDA and the EMA. We retrospectively analyzed 37 DSCs of 41 adverse drug reactions (ADRs) for 33 drugs in Japan from 1997 to 2022. Most DSCs were related to non‐oncology drugs (30/37, 81.1%), and the median (interquartile range) time from approval to DSC issuance was 19 (10–51) months. Notably, the regulatory review reports and the latest labels before DSC issuance did not describe 16/28 (57.1%) and 12/37 (32.4%) of the ADRs related to DSCs, respectively. Most DSCs resulted in label revisions (36/37, 97.3%) and seven drugs were eventually withdrawn. Some DSC characteristics are similar among the PMDA/MHLW, the FDA, and the EMA; however, the number, contents, and range of new safety issues addressed by DSCs differ among the three jurisdictions. Our study emphasized the importance of continuous efforts to gather postmarket drug safety information because substantial ADRs that led to DSCs were recognized after approval and were associated with critical label revisions and withdrawals. Future studies are required to address global challenges for regulatory harmonization of safety‐related regulatory actions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clinical and Translational Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
- Office of Pharmacovigilance, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
ORCID-Profile: Mototsugu Tanaka
Förderung
- JSPS KAKENHI
Zitieren
APA
Tanaka, Y., Tanaka, M., Miyazawa, H., Terashima, R., Miyazawa, M., Ikuma, M., & Tomita, Y. (2024). Postmarket safety communications on drugs approved in Japan: A 25‐year analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.13803
Vancouver
Tanaka Y, Tanaka M, Miyazawa H, Terashima R, Miyazawa M, Ikuma M, et al. Postmarket safety communications on drugs approved in Japan: A 25‐year analysis. Clinical and Translational Science. 2024. doi:10.1111/cts.13803
BibTeX
@article{Tanaka2024,
author = {Tanaka, Yusuke and Tanaka, Mototsugu and Miyazawa, Haruna and Terashima, Ryohei and Miyazawa, Makoto and Ikuma, Mutsuhiro and Tomita, Yoshihiko},
title = {Postmarket safety communications on drugs approved in Japan: A 25‐year analysis},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13803}
}
EUVIMED